The relation between pregnancy outcome and single- or double-positivity of anticardiolipin (aCL) and β2 glycoprotein I (aβ2GPI) in antiphospholipid syndrome (APS) has yet to be clearly documented. In this article, a total of 191 lupus anticoagulant-negative pregnant women with primary APS were retrospectively divided into three groups: aCL+/aβ2GPI−; aCL+/aβ2GPI+; aCL−/aβ2GPI+. All women had received medical therapy consisting of prednisone (10–15 mg/day), low-dose aspirin (50 mg/day), and low molecular weight heparin (40 mg/day). The miscarriage rate in the double-positive group was significantly higher than that in the aCL+/aβ2GPI− group (46.2% vs. 22.1%, p < 0.05); the miscarriage rate in the aCL−/aβ2GPI+ group (36.4%) was not significantly different from the rates of the other two groups (p > 0.05). Thus, double-positivity may be a risk factor for pregnancy loss and aβ2GPI antibody may be a better prognostic marker than aCL antibody for pregnancy outcome.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.